Replies to post #505201 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

We all need to recognize that the NYAS and other subsequent
presentation did not present all the data, it only presented what was permitted based on what is sequestered. That is exemplified by the lack of patients meeting the Top 100 figures previously discussed by Drs Liau and Ashkan. I mentioned that after my last discussion with DI.

I believe that the TLD statement will have far more in it than we have seen to date.

Gary

[dennisdave]

I guessed you missed the NYAS (and other) presentations that clearly disagreed with your post,

I guess you really are in need of reading glasses. No better reality check. From the NY Conference:

Secondary Endpoint: OS in recurrent GBM
Placebo arm crossovers* (n=64) vs. External controls (n=640)
*(Placebo arm patients received only SOC (control arms of external studies)
+ placebo until recurrence, then DCVax-L)

At the NY conference, the secondary endpoint for nGBM was not mentioned. Get a pair of reading glasses, +5 will do. If you are eager to learn with the second endpoints for nGBM is

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169688051
EU/UK and US endpoints do not differ

EU/UK/
The first secondary objective is to compare overall survival (OS) between patients randomized to placebo who received DCVax-L treatment following disease recurrence and control patients from comparable, contemporaneous clinical trials, in patients with recurrent GBM.

US
1. The first secondary objective is to compare overall survival (OS) between patients randomized to placebo who received DCVax-L treatment following disease recurrence, and control patients from comparable, contemporaneous clinical trials, in recurrent GBM.
[ Time Frame: Until death ]

exact the same
It has been stated more than once by the company and LL that the SAP is the same with every RA